Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta‐analysis of Randomized Controlled Trials

Author:

Sardar Partha1,Udell Jacob A.23,Chatterjee Saurav4,Bansilal Sameer5,Mukherjee Debabrata6,Farkouh Michael E.3

Affiliation:

1. Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT

2. Cardiovascular Division, Department of Medicine, Women's College Hospital, University of Toronto, Ontario, Canada

3. Peter Munk Centre of Excellence in Multinational Clinical Trials, University Health Network, Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Ontario, Canada

4. Division of Cardiovascular Diseases, St. Luke's‐Roosevelt Hospital Center of the Mount Sinai Health System, New York, NY

5. Cardiovascular Institute, The Mount Sinai Medical Center, New York, NY

6. Division of Cardiovascular Diseases, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX

Abstract

Background Regional variation in type 2 diabetes mellitus care may affect outcomes in patients treated with intensive versus standard blood glucose control. We sought to evaluate these differences between North America and the rest of the world. Methods and Results Databases were searched from their inception through December 2013. Randomized controlled trials comparing the effects of intensive therapy with standard therapy for macro‐ and microvascular complications in adults with type 2 diabetes mellitus were selected. We calculated summary odds ratios ( OR s) and 95% CI s with the random‐effects model. The analysis included 34 967 patients from 17 randomized controlled trials (7 in North America and 10 in the rest of the world). There were no significant differences between intensive and standard therapy groups for all‐cause mortality ( OR 1.03, 95% CI 0.93 to 1.13) and cardiovascular mortality ( OR 1.09, 95% CI 0.90 to 1.32). For trials conducted in North America, intensive therapy compared with standard glycemic control resulted in significantly higher all‐cause mortality ( OR 1.21, 95% CI 1.05 to 1.40) and cardiovascular mortality ( OR 1.41, 95% CI 1.05 to 1.90) than trials conducted in the rest of the world (all‐cause mortality OR 0.93, 95% CI 0.85 to 1.03; interaction P=0.006; cardiovascular mortality OR 0.89, 95% CI , 0.79 to 1.00; interaction P=0.007). Analysis of individual macro‐ and microvascular outcomes revealed no significant regional differences; however, the risk of severe hypoglycemia was significantly higher in trials of intensive therapy in North America ( OR 3.52, 95% CI 3.07 to 4.03) compared with the rest of the world ( OR 1.45, 95% CI 0.85 to 2.47; interaction P=0.001). Conclusion Randomization to intensive glycemic control in type 2 diabetes mellitus patients was associated with increases in all‐cause mortality, cardiovascular mortality, and severe hypoglycemia in North America compared with the rest of the world. Further investigation into the pathobiology or patient variability underlying these findings is warranted.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3